Skip to main content
Back
JNJ logo

Johnson & Johnson

Data quality: 100%
JNJ
NYSE Healthcare Drug Manufacturers - General
$235.42
▲ $0.05 (0.02%)
Mkt Cap: 567.34B
Day Range
$234.25 $238.31
52-Week Range
$141.50 $251.71
Volume
7,301,338
50D / 200D Avg
$234.14 / $194.58
Prev Close
$235.37

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 21.2 0.4
P/B 7.0 2.9
ROE % 35.0 3.8
Net Margin % 28.5 3.9
Rev Growth 5Y % 4.6 10.0
D/E 0.6 0.2

Analyst Price Target

Hold
$228.73 -2.8%
Low: $190.00 High: $265.00
Forward P/E
20.4
Forward EPS
$11.56
EPS Growth (est.)
+0.0%
Est. Revenue
100 B

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $16.71
$16.10 – $17.19
 130 B 2
FY2029 $15.06
$14.51 – $15.49
 120 B 2
FY2028 $13.73
$10.81 – $16.03
 110 B 5

Insider Trading Activity

Buy ratio (90d) 0.0%
13 transactions
Date Insider Type Shares Price Value
Feb 27, 2026
Decker Robert J
VP Corporate Controller
 other 8,150 $115.67 —
Feb 27, 2026
Decker Robert J
VP Corporate Controller
 sell 4,075 $247.87 $1,010,070
Feb 20, 2026
Schmid Timothy
EVP, WW Chair, MedTech
 sell 1,322 $245.66 $324,763
Feb 9, 2026
Decker Robert J
VP Corporate Controller
 grant 2,741 — —
Feb 9, 2026
Broadhurst Vanessa
EVP, Global Corp Affairs
 grant 8,594 — —
Feb 6, 2026
Mulholland Kristen
EVP, Chief HR Officer
 other 14,585 $101.87 $1,946,404
Nov 26, 2025
MORIKIS JOHN G
Director
 buy 1,250 $206.15 $257,688
Sep 9, 2025
Woods Eugene A.
Director
 grant 211 $178.07 $37,573
Jul 17, 2025
REED JOHN C
EVP, Innovative Medicine, R&D
 sell 19,137 $163.55 $3,129,830
Jun 10, 2025
HEWSON MARILLYN A
Director
 grant 322 $155.23 $49,984
Apr 24, 2025
WEINBERGER MARK A
Director
 grant 1,316 — —
Apr 24, 2025
McClellan Mark B.
Director
 grant 1,316 — —
Apr 24, 2025
Woods Eugene A.
Director
 grant 1,316 — —

Key Takeaways

Revenue grew 4.58% annually over 5 years — modest growth
Earnings grew 90.56% over the past year
ROE of 35.03% indicates high profitability
Net margin of 28.46% shows strong profitability
Generating 19.70B in free cash flow
PEG of 0.21 suggests growth is underpriced

Growth

Revenue Growth (5Y)
4.58%
Revenue (1Y)6.05%
Earnings (1Y)90.56%
FCF Growth (3Y)3.90%

Quality

Return on Equity
35.03%
ROIC14.83%
Net Margin28.46%
Op. Margin27.17%

Safety

Debt / Equity
0.59
Current Ratio1.03
Interest Coverage26.36

Valuation

P/E Ratio
21.17
P/B Ratio6.96
EV/EBITDA23.27
Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 6.05% Revenue Growth (3Y) 5.17%
Earnings Growth (1Y) 90.56% Earnings Growth (3Y) -12.68%
Revenue Growth (5Y) 4.58% Earnings Growth (5Y) 6.45%
Profitability
Revenue (TTM) 94.19B Net Income (TTM) 26.80B
ROE 35.03% ROA 13.46%
Gross Margin 72.78% Operating Margin 27.17%
Net Margin 28.46% Free Cash Flow (TTM) 19.70B
ROIC 14.83% FCF Growth (3Y) 3.90%
Safety
Debt / Equity 0.59 Current Ratio 1.03
Interest Coverage 26.36 Dividend Yield 0.02%
Valuation
P/E Ratio 21.17 P/B Ratio 6.96
P/S Ratio 6.02 PEG Ratio 0.21
EV/EBITDA 23.27 Dividend Yield 0.02%
Market Cap 567.34B Enterprise Value 595.56B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 94.19B 88.82B 85.16B 79.99B 78.74B
Net Income 26.80B 14.07B 35.15B 17.94B 20.88B
EPS (Diluted) 11.03 5.79 13.72 6.73 7.81
Gross Profit 68.56B 61.35B 58.61B 55.39B 55.34B
Operating Income 25.60B 22.15B 23.41B 21.01B 20.94B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 199.21B 180.10B 167.56B 187.38B 182.02B
Total Liabilities 117.67B 108.61B 98.78B 110.57B 108.00B
Shareholders' Equity 81.54B 71.49B 68.77B 76.80B 74.02B
Total Debt 47.93B 36.63B 29.33B 39.64B 33.75B
Cash & Equivalents 19.71B 24.11B 21.86B 12.89B 14.49B
Current Assets 55.62B 55.89B 53.50B 55.29B 60.98B
Current Liabilities 54.13B 50.32B 46.28B 55.80B 45.23B